Long-term survival after luveltamab tazevibulin, a novel folate receptor-α (FRα) targeting antibody drug conjugate (ADC) in children with CBFA2T3::GLIS2 acute myeloid leukemia (AML).

Authors: Robin Lesley Williams, Lane Miller, Stephanie Massaro, Elizabeth Krieger, Melinda Gordon Pauly, Catherine Nelson, Rebecca Johnson, Jennifer J.G. Welch, Deepa Bhojwani, Babak Moghimi, Philip Neff, Terzah Horton, Hamayun Imran, Raul Correa Ribeiro, Terri Guinipero, Felipe Bautista, Matthew Kutny, Amy J. Johnson, Karen Lewing, Soheil Meshinchi

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e22007

Source: Full article

---

Abstract

e22007